Introduction
Lung cancer is the leading cause of cancer deaths among men and women in America (Jemal et al., 2002) . There are four major histological subtypes of human lung cancer: small-cell carcinoma (SCLC), adenocarcinoma (AC), squamous cell carcinoma (SCC), and large-cell carcinoma (LCC). Several animal models have been developed to study lung carcinogenesis, especially the development of ACs. Use of chemical carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in a lung tumor-susceptible murine strain, such as A/J, consistently produces histologically similar lung adenomas and ACs in a time-dependent manner (Malkinson, 1992) . Adenomas observed in the A/J mouse model have been shown to be histologically similar to atypical adenomatous hyperplasia, the premalignant precursor of bronchiolo-alveolar carcinomas found in humans (Travis et al., 1999) .
Mouse lung tumors have been shown to have accumulation of genetic changes, including mutations of cancer genes such as K-ras, p16 ink4a , and p53, as well as multiple sites of genomic deletions (Dragani et al., 1995) . While some of the specific major genetic effectors of lung tumorigenesis have been characterized, more complete or systematic examination of RNA or protein expression have not been performed particularly in animal models. These changes are important to understand, since they may yield the means for therapeutic intervention. The dysregulation or loss of one gene affects the function of many other genes due to the complexity of interactions between various genes, their effectors, and the pathways that they regulate or participate in. To produce a transcriptome-wide observation of the complicated process of lung carcinogenesis, we have used oligonucleotide arrays. The microarray technology has widened the doorway through which researchers observe cellular machinery, helping to form a more complete picture of gene interactions and regulation with a global view of gene expression. Using Affymetrix Murine U74Av2 GeneChips, we compared gene expression in murine adenomas and ACs with normal lungs. In this manner, we hope sought to find novel gene interactions and to gain a clearer picture of the events that foster disease progression. Specifically, this study was designed to examine novel genes involved in both initiation of lung cancer and its progression to a more aggressive cancer phenotype.
Furthermore, we have examined another aspect of carcinogenesis: 'dedifferentiation'. Cancerous cells have often been referred to as being dedifferentiated and expressing embryonal antigens. The genetic changes that lead to disease change the properties of the lung cell, making it more closely related in both morphology and function to a stem cell. Tumorigenesis can be imagined to mirror lung organogenesis, in that both processes have exponential growth phases, the cell masses in both processes are able to recruit their own blood supply, and the resulting tissue mass can function as a distinct entity (for example, tumors that develop neuroendocrine functions). Accordingly, we have compared gene expression data from mouse lung tumors to results from a previous study that reported gene expression changes observed during lung organogenesis from embryonic development, until development of normal adult lung (Bonner et al., 2003) . In the present study, we used the same microarray-based approach to examine the expression of 1346 genes, previously identified as being important in lung development, in our lung tumor progression samples.
Finally, we have compared gene expression in human lung cancer samples (Virtanen et al., 2002) with expression of orthologous genes in the mouse to determine the similarity between lung tumor formation in mice and humans. Histologically, murine adenomas have been reported to most closely resemble bronchioloalveolar carcinomas in the human, but all of the human non-small-cell lung carcinomas have some properties in common with the murine tissues (Malkinson, 1992) . From a study done using human lung samples by Virtanen et al. (2002) , we obtained gene expression data from one bronchiolo-alveolar AC (BAC), 16 ACs, and six LCCs, and compared their expression to various stages in our murine model of lung cancer progression. Our goal is to identify similarities in murine and human lung cancer progression in order to better understand the overall process of lung cancer development.
The present study should provide a better understanding of the complicated processes that contribute to lung tumor development and disease progression. Furthermore, it may identify genes which are common to both murine and human lung cancer, which may serve as therapeutic and preventive targets that can readily be examined in this rodent model.
Materials and methods

Tumor tissues
Lung adenomas (ADE) and normal lungs (N1) were collected from (A/J Â 129/SvJ) F 1 mice in which mice were terminated approximately 6 months after carcinogen treatment (Zhang et al., 2000) . Normal lungs (N2) and lung ACs (CAR) were collected from (A/J Â C3H/HeJ) F1 mice in which mice were terminated approximately 14 months after carcinogen treatment (You et al., 1992) . Both lung adenomas and ACs were obtained from mice treated with NNK, a tobacco-specific nitrosamine, according to dose-sacrifice schedule described elsewhere (You et al., 1992; Zhang et al., 2000) . Lung tumors were collected, frozen in liquid nitrogen and then stored at À801C. Before freezing, a representative portion of each tumor was fixed in neutral buffered 10% formalin for histopathological examination. Normal lungs were collected from age-matched animals in the same experiment the tumors were collected (You et al., 1992; Zhang et al., 2000) .
RNA collection and amplification
Frozen tissue samples were pulverized and total cellular RNA was collected from each flash frozen sample, using TRIzol RNA isolation reagent (Life Technologies). Total RNA was cleaned up with a Qiagen RNeasy Mini kit (Cat ID 74104). In vitro transcription-based RNA amplification was then performed on each sample. cDNA was synthesized using the T7-(dT)24 primer 5 0 -GGCCAGTGAATTGTAATACGACT CACTATAGGGAGGCGG-(dT)24-3 0 . The cDNA was cleaned using phase-lock gel (Fisher Cat ID E0032005101) phenol/chloroform extraction. After clean up, in vitro transcription labeling was performed using the Enzo 'Bioarray Kit' (Affymetrix, Cat ID 900182). The resulting cRNA was purified, again using the Qiagen RNeasy Mini kit.
Affymetrix GeneChip probe array
RNA samples were hybridized to Affymetrix Mu74Av2 GeneChips, according to the manufacturer's recommendations. Approximately 16 probe pairs (oligonucleotides) represent every gene or EST in a probe set. One sequence represents the complementary strand of the target sequence, while the other has a one base pair mismatch at the central base pair position. This mismatch sequence serves as an internal control for specificity of hybridization. The relative expression is reported as the average difference of the fluorescence intensity values between the perfect match and the mismatch oligonucleotides resulting in the 'average difference' value (Lockhart et al., 1996; Wodicka et al., 1997) .
Statistical analysis
The Li-Wong full model was used to obtain a basal expression level (Li and Wong, 2001) . The basal expression level was used to assess gene expression changes between the following sample sets: non-tumor (N1 and N2) versus tumor (ADE and CAR), normal lung (N1) versus adenoma (ADE), normal lung (N2) versus carcinoma (CAR), and adenoma (ADE) versus carcinoma (CAR). Fold change was the ratio between the average expression values for two sets of tissues. Genes related to immune function were not examined in this study. The statistical significance of gene expression differences between groups was determined by t-test.
Analysis was also performed to examine the relationship between lung development and lung carcinogenesis. The original lung development analysis was performed previously, and comprised data from seven groups of tissues: embryonic day 9 (9D), embryonic day 14 (14D), embryonic day 17 (17D), newborn (NB), 1 week postnatal (1W), 2 weeks postnatal (2W), and 4 weeks postnatal (4W) (Bonner et al., 2003) . In that study, 1346 genes were identified as having significant expression changes between one time point and another using the Kruskal-Wallis test (Po0.001). The expression values of the 1346 genes were collected for the murine lung tumor progression samples and the expression patterns were compared to the lung development samples.
To minimize the influence of false positives in this study, multiple criteria were used to assess genes, such as fold change and significance, and the fold-change observations for a subset of genes were independently validated using RT-PCR.
Mouse-human comparison
A subset of previously reported gene expression data from human tissues was compared with data from the mouse (Virtanen et al., 2002) . Data from human tissues included one BAC, 16 ACs, and six LCCs, as they are appeared in Supplementary spreadsheet 1 for Figure 1 on PNAS website (Virtanen et al., 2002; www.pnas.org) . To make the human cDNA array data comparable to the mouse oligonucleotide array data, both data sets were transformed to relative scales by dividing the expression values for each gene by the data set average for the gene. These relative expression values were then log-transformed for further analysis. Human-mouse homologs were determined using the NCBI HomoloGene database (www.ncbi.nlm.nih.gov/HomoloGene/), which produced 1927 genes in both data sets. Hierarchical clustering was performed using the Cluster program and visualized using the TreeView program (Eisen et al., 1998) . Both programs were obtained from the Eisen laboratory at the University of California at Berkeley (http://rana.lbl.gov/index.htm). To identify genes with expression pattern in mouse similar to the pattern in human, t-tests comparing the normal with tumor were performed. Genes with Po0.01 in both human and mouse, and with the same direction of expression change, were identified.
Synthesis of cDNA
A measure of 2 mg of total RNA per sample, collected as described above, was converted to cDNA using the SuperScript First-Strand Synthesis system for RT-PCR (Invitrogen, Cat. No. 11904-018) . The primer used to generate cDNA was the same as that used to generate cDNA for the oligonucleotide array assay (T7-(dT) 24 primer: 5 0 -GGCCAGTGAA TTGTAATACGACTCACTATAGGGAGGCGG-(dT) 24 -3 0 ). cDNA generated from each of the samples comprising one group was then pooled and real-time PCR was performed.
Real-time PCR
The real-time PCR assay was performed using the BioRad iQ SYBR Green Super Mix kit (BioRad, Cat. No. 170-8880). The following primers were used to amplify the genes of interest: APC2 F-TGAGACAGTCAAGCGGTACG, R-GGAGGC TTGGTGA GTACTGG; BNIP2 F-TGAGCTTCTCCTC CCTGAAA, R-GCACTGTACACCACCCAA CA; CDK4 F-CTCACGCCTGTGGTGGTTAC, R-CACTCTGCGTCG CTTTCCT; CYC1 F-CAGATGGACAGCTCCCAGTT, R-TCTCAC CCCGAGTAGTCAGC; DCN F-TAAC TGCG ATCCCTCAAGGT, R-AGGCCGTCTGAGGGTTACTT; ETS2 F-CAATTCTG GAAAACCCAAGG, R-CGGCTCAG CTTCTCGTAGTT; HOX6 F-CTTGTCTGCAGG AGCCC TA, and R-ATTCGAGAACGGATCCAGAG. A volume of 1 ml of pooled cDNA was added to a 25 ml total volume reaction mixture containing water, iQ SYBR Green Super mix, and primers. Each real-time assay was performed in triplicate. The data were collected and analysed on the Biorad iCycler version 2.033. GAPDH (primers: F-TGGAGAAACCTGC CAAGTATG, R-GTGGGTGCAGCGAACTTTAT) was used as an internal standard. The GAPDH value, a reflection of the number of cycles needed to reach a threshold of fluorescence, was subtracted from the cycle value for the individual gene, whose expression was being assessed. Fold change was assessed by dividing the expression value or the real-time value for the cancerous tissues by the values generated for the age-matched control tissues. For the calculation of the foldchange values in Figure 4 , the age-matched sample N1 was used for the control value for the ADE sample and the agematched sample N2 was used as the control value for the CAR sample.
Results
The first goal of this study was to determine gene expression changes during lung tumor development. Figure 1a and Table 1 list those genes whose difference in expression between the tumors (ADE and CAR) and normal lungs (4W, N1 and N2) have a P-value of less than 0.001. In this figure, there are 15 genes whose expression was decreased and five genes whose expression was increased in the cancerous tissues. The majority of the genes on this list has previous associations with a certain type of cancer, such as APC2 and colon cancer development, but has not, as yet, been linked to the development of lung cancer. Interestingly, we saw a decrease in the apoptosis-associated genes melanoma differentiation-associated protein 5 (MDA 5) and endonuclease G, as well as the cell cycle control regulator guanylyl cyclase C. We saw increased expression in genes such as the Ros 1 proto-oncogene, a phosphotyrosine kinase, and p204, a gene related to DNA replication. Figure 1b and Table 1 list those genes that we have found to be associated specifically with the progression of murine lung cancer from adenoma to carcinoma. There were 25 genes whose expression was decreased in carcinomas, including important differentiation-associated genes such as Homeobox C6 and Wingless-related MMTV Integration Site 6 (WNT6). Crystallin lambda 1 was also downregulated in the carcinomas, and has previously been shown to be downregulated in liver cancers (Chen et al., 2003) . We also identified 25 genes whose expression is increased in carcinomas. Several of these genes have been previously identified as being oncogenic in nature, such as E26 Avian Leukemia Oncogene 2 (ETS2) and Nuclear Transport Factor 2, the nuclear importer of oncogenic Ras (Wurzer et al., 2001) . Also, the tumor cell migration factor ADAM10 was upregulated in the carcinomas. One other interesting aspect of these studies is that the fold increases in tumors in genes overexpressed in carcinomas tended to be higher than the fold differences in expression in genes more highly expressed in adenomas than carcinomas.
The next phase of our study involved the analysis of carcinogenesis in the context of murine lung development. We previously examined gene expression changes during murine lung development at key developmental stages (Bonner et al., 2003) . Noting similarities between lung carcinogenesis and lung development, such as relatively rapid growth, vasculature remodeling, and tissue structure change, we hypothesized that genes identified as being involved in lung development also play key roles in carcinogenesis. In Figure 2a , the overall expression pattern and hierarchical clustering of the 1345 genes we identified as being developmentally regulated in the lung are shown (Bonner et al., 2003) . The overall patterns of expression observed here, as defined by the cluster order of the genes, are quite different from those seen in the developmental samples, which may be expected since the tumorigenic and organogenic environments can be expected to be quite different. Figure 2c is an expanded portion of 2b, detailing genes and ESTs whose expression is considerably higher in the carcinoma samples than in the rest of the samples. Factors that encourage growth, such as Arginase 1 and epidermal growth factor receptor, are upregulated in the murine carcinomas. Interestingly, 
Identification of genes associated with lung tumor development and progression. (a) Genes associated with the development of murine lung tumors. The expression of genes in normal adult lungs at various time points is compared to gene expression in cancerous murine lung tissues. Red -increased expression when compared with the mean expression values for the data set. Greendecreased expression when compared with the mean expression values for the data set. Black -similar expression to the mean expression values for the data set. Probe ID -Affymetrix probe identification number. Pub Access -public accession number that corresponds to the Affymetrix Probe ID. The samples names are as follows: 4W -lung tissue collected from 4-week-old adult mice (in order 4W1, 4W2, 4W3, 4W4); N1-normal lungs, age matched to the adenoma samples (in order N1-1, N1-2, N1-3); N2 -normal lungs, age matched to the carcinoma samples (in order N2-1, N2-2, N2-3); ADE -murine lung adenoma tissue (in order ADE1, ADE2, ADE3); CAR -murine lung AC samples (in order CAR1, CAR2, CAR3). Unless otherwise noted, the order of the samples for all figures is as listed. (b) Identification of novel genes involved in the progression of murine lung cancer. Color scheme and labels are identical to part (a) The left-hand set of genes are those genes that correspond to the genes listed in Figure 1a . The fold changes were determined by dividing the average of the expression values from the normal tissues by the average of the values from the cancerous tissues. In the middle and right-hand columns, the genes correspond to those listed in Figure 1b . The middle column gives the fold change between those genes whose average expression is higher in the adenomas than in the carcinomas. The far right column is a list of the fold changes associated with those genes whose average expression is higher in the carcinomas than in the adenomas. Note that only a selected group of genes from the figures are presented in the tables. FC, fold changes CDK4 gene expression, whose function is usually associated with proliferation, is upregulated, as is tripartite motif protein 28, also known as TIF1. Figure 2d and Table 2 show 24 genes whose expression patterns in tumors are the opposite of those found in the developmental process. These include three The same genes identified in (a), but with expression values from the murine lung tumor samples collected for this paper. (c) Genes identified as being involved in lung development in (a), whose expression is markedly increased in the mouse lung carcinoma samples. (d) Identification of potential oncogenes and tumor suppressors based on the reversal of the expression pattern seen in the lung-development samples (P-value o0.001). 9D -9-day postconception, 14D -14-day postconception, 17D -17-day postconception, NB -new born, 1W -1-week postnatal, 2W -2-week postnatal, and 4W -4-week postnatal. N1, N2, ADE, and CAR are as described in Figure 1 . Color scheme and labeling of columns is as stated in Figure 1 genes that are overexpressed in early development, underexpressed in adult lung and are again overexpressed in adenomas or carcinomas (cell division cycle 5, zinc-finger protein 239 and ubiquitin finger protein A). The three genes whose expression is upregulated in the cancerous tissues include CDC5, a cell cycle effector needed for exit out of mitosis, zincfinger 239, also known as MOK-2, a zinc-finger transcription factor possibly involved in cell transformation, and ubiquitin-binding protein A, involved in protein degradation. There is a much wider group of genes that were underexpressed in early development, overexpressed in adult lung and are again under expressed in adenomas or carcinomas. Genes downregulated in the cancerous samples have various roles. MAP kinase-activated protein kinase 5 is involved in cell cycle control. TEA Domain 4 (TEAD 4) is involved in cellular differentiation. BCL2/adeovirus E1B-interaction protein 1 (bnip2) is a proapoptotic factor. Histone deacetylase 5 is a transcription blocker. All of these genes function in concert to control cell growth and regulate the detection and repair of DNA damage. Finally, we examined our murine lung cancer model in the context of human lung carcinogenesis, as previously reported (Virtanen et al., 2002) . We examined the BAC, the various AC subtypes, and the LCCs for our comparison for the following reasons: BAC is thought to be closely related to murine lung AC, since both cancers arise from Type II and Clara cells. Figure 3a shows two-way hierarchical clustering of both mouse and human gene expression data. A group of 14 ACs clustered together with mouse lung adenomas (ADE1-3). This is then followed by a second group of four ACs and six LCCs clustered together with mouse lung carcinomas (CAR1-3). It is quite obvious from this figure that gene expression in the murine lung tissues varies greatly from that in the human lung tissues. Figure 3b and Table 3 list the expression patterns, public accession numbers, and gene names of 39 homologous genes whose expression patterns appear similar in the murine and human tissues. In all, 21 genes show decreased expression and 18 genes show elevated expression in the cancerous tissues. In the mouse, the increased expression was detected mainly in the carcinoma samples. One of the adenoma samples had similar expression patterns as the carcinoma, indicating that this particular sample may be progressing molecularly to a carcinoma. Of the 18 genes with an average increased expression in both the murine and human carcinoma samples, at least four are involved in cell metabolism, for example, S-adenosylhomocysteine hydrolase. Several cell cycle effectors such as CDK4 and CDC2, and a member of the antiapoptotic BCL family, BCL 7b, were also upregulated in these tissues. For genes that had decreased expression in the cancer samples, there seemed to be a more uniform decrease in expression for both the murine and human tissues. As for the previous group of genes whose expression was upregulated in the cancerous tissues, several were metabolic genes, such as aldehyde dehydrogenase A1, C-4 methyl sterol oxidase, and 2-N-acetylglucoaminyltransferase.
More importantly, there are several genes currently under investigation for their various roles in cancer formation and/or progression that have reduced expression in tumor tissues. LHL four-and-half LIM domains 1 (FHL1) plays a critical role in cellular differentiation. We observed this gene's expression highly downregulated in all but one of our ACs, and all of the LCC samples in the human tissues. This decrease in expression was not nearly as prevalent in the BAC sample. The murine tissues also had highly decreased expression of this gene. IkBa is an inhibitor of the antiapoptotic factor NF-kB. Its expression was higher in the cancers compared to normal lungs in both mice and humans. Semaphorin 3b is a known tumor-suppressor gene found on human chromosome 3p21.3, and its expression reduced in the murine adenomas as well as in several of the human ACs and LCC samples. The occurrence of the decrease in apoptotic signaling, the decrease in differentiation signals, as well as the reduction in tumor suppression could be a key combination in the progression of murine tumors and human ACs.
In order to verify our microarray results, we performed real-time RT-PCR on a subset of the genes identified in Figures 1-3 FC-LD -fold changes between the averages of the prenatal and postnatal expression values for the murine lung development genes. FC-MLT -fold change between the averages of the normal and cancerous expression values for the murine lung development genes protein 1 (BNIP2); Figure 3 : CDK4]. The real-time RT-PCR results presented in Figure 4 show that expression trends for the selected genes in both the microarray assay and the real-time RT-PCR assay are strikingly similar, confirming the microarray results. We have also performed the Pearson correlation coefficient test Figure 1 . Human tissue labeled as follows: ACadenocarcinoma, BAC -bronchiolo-alveolar adenocarcinoma, LCC -large-cell carcinoma. Numbers after the human tissue samples indicate the particular sample identifier. Color scheme identical to that described in Figure 1. (b) Detailed analysis of human geneexpression patterns that are similar to murine. Murine sample information is on the left side of the figure. To the right of the expression diagram are the murine public accession numbers that refer to the gene being displayed. The labeling of the tissues is identical to that in Figure 1 . The right side of the figure displays the expression patterns of the human tissues. The human public accession number is to the right of the expression diagram. To the far right of the figure is the name of the gene being examined between the array and RT-PCR fold-change values and r 2 ¼ 0.80. Nevertheless, the real-time RT-PCR assay was only performed for a selected group of genes, and it is not clear how representative they are for all the other observed differentially expressed genes.
Discussion
This study examined the oligonucleotide array technology to look at three separate but potentially related questions:
(1) what are the differences in gene expression observed between mouse lung adenomas and mouse lung ACs (Figure 1 and (Figure 1 and Table 1 ) that are involved in the progression of lung cancer in mice, from adenoma to carcinoma. This list includes a loss of expression for genes whose functions are vital to cell cycle checkpoints, such as Excision Repair 2, and differentiation factors, such as Homeobox C6 and Wnt 6. We also saw an increased expression of known oncogenes, such as Ets 2 and Nuclear Transport Factor 2, in the lung carcinoma. Other genes with increased expression in carcinoma tissue include FLAP 1, Klf 4, and metallothionein 2. These putative novel oncogenes, or similar family members, may play important roles in Both the murine and human public accession numbers are given (Mouse Pub Acc and Human Pub Acc), as well as the fold change between the normal and cancerous tissues in both the murine and human studies. FC, fold change; MLT, mouse lung tumors; HLT, human lung tumors the development of other types of cancers as well. We have also observed new gene interactions during lung tumorigenesis. The loss of APC2 has been seen previously in lung cancer (Miura et al., 2002) , but genes such as endonuclease G, involved in apoptosis, guanylyl cyclase C, involved in the suppression of cell growth, and MDA 5, involved in both apoptosis and cell growth control, are novel effectors of lung tumorigenesis. Ros 1, a receptor-like proto-oncogene with tyrosine kinase catalytic domains, has been shown to have transient expression during development in the lung, which coincides with the major morphogenetic and differentiation events (Sonnenberg et al., 1991) . This study also examines the role of developmentally regulated genes in lung carcinogenesis. The development of cancer is very similar to the development of an organ. Once the cancer cell has been transformed, it usually takes on the characteristics of a less differentiated and/ or an undifferentiated cell, and may also exhibit the higher level of proliferation that is similarly associated with embryonic development. In the case of both the organ stem cell and the dedifferentiated cancer cell, there is a dramatic remodeling of the cell cycle machinery to drive the growth of the cell in a particular direction. In the case of the cancer cell, this drive is mediated through the loss of cell cycle checkpoint factors, DNA repair genes, and antiapoptotic signaling initiated by the damaging agent. The tissues that derived from both the tissue stem cell and the cancer cell use the change in cell cycle machinery to recruit novel blood supplies and grow in an exponential fashion. The genes in Figure 2c are those whose aberrant expression enables the cell to overcome differentiation signals put in place at the termination of organ development. The functions of these genes are varied, suggesting that conversion to tumor phenotype effects many cellular functions also observed as following a program during organogenesis. For example, this list includes a variety of metabolism genes to fuel the hyperproliferative tissues, transcription factors that initiate aberrant growth, and factors that help the cancerous tissue evade apoptosis. By understanding how these genes work in development, it may be possible to understand the role that they play in helping cancerous cells increase their growth potential, and may reveal therapeutic targets.
We hypothesized that dysregulated developmental genes may play an important role in carcinogenesis. For example, a gene involved in cellular differentiation that is aberrantly downregulated in an adult cell could cause that cell to dedifferentiate, which, in turn, could lead to tumor formation after a period of excessive growth. In contrast, a gene whose expression is upregulated in the adult cell when it had been silenced after prenatal development could disrupt the cell's growth and allow it to escape cell cycle control mechanisms to the point where carcinogenesis occurs. Thus, those genes that were identified as being imperative for lung development, and whose expression is increased in the prenatal period, may have an oncogenic function in adult tissue, while developmental genes whose expression is increased in the postnatal period may have a tumor-suppressor function in the adult tissue. The comparison of geneexpression differences at different stages of development and in tumors supports the general theory of a relationship between carcinogenesis and embryogenesis. Thus, a variety of genes, which were differentially expressed during fetal development as compared with 4-week-old or adult lung, recapitulate their fetal pattern during carcinogenesis. In this part of the study, we identified 24 new lung tumor effectors, three novel oncogene candidates, and 21 novel tumor-suppressor candidates in the murine lung. We identified decreased expression of TEAD 4, a gene involved in cellular differentiation as well as BCL2/adenovirus E1B-interacting Protein 1 (NIP2), a proapoptotic factor. Expression of histone deacetylase 5 is also decreased in the cancerous tissue. The expression of zinc-finger protein 239 (MOK2), a transcription factor involved in cellular transformation, was increased in the murine cancer samples. These examples show the involvement of developmental genes in cancer development.
Finally, the relationship between murine lung tumor formation and human lung cancer development was examined. A clear understanding of disease progression in both systems is needed to inform studies in cancer chemoprevention and treatment using animal models. Figure 3 demonstrates the degree to which murine lung cancers are similar to a subpopulation of human lung cancers, and reveals some very interesting implications. First, in the humans, 14 lung ACs fall into one distinct group by clustering together with mouse lung adenomas, while the remaining four lung ACs and six LCCs fall into a second group, together with mouse lung ACs. This certainly raises the possibility that gene-expression pattern of mouse lung adenomas may resemble those ACs with lower-grade well-differentiated pathological features. Similarly, the gene-expression pattern of mouse lung ACs may resemble those ACs and LCCs with more aggressive pathological features. Nevertheless, when Figure 4 A fold-change comparison of microarray expression data and real-time PCR expression data for a representative group of genes identified as being involved in various aspects of lung cancer using data generated from the analysis of murine tissues. The blue bars represent microarray expression data. Purple bars represent real-time PCR expression data. The gene whose expression being analysed is indicated on the X-axis comparing mouse lung tumors and all human lung ACs and LCCs in both murine and human data sets, CDK4 is substantially upregulated in the advanced murine cancer tissues (carcinomas) as well as in the majority of the human advanced cancer tissues (LCCs) and several of the ACs. CDK4 phosphorylates Rb, activating E2F transcription factors and inducing cell cycle progression. Not only is CDK4 expression increased, but CDC2 is also upregulated. CDC2 inactivates major anabolic processes such as transcription and mRNA processing, and activates the cell cycle. Its aberrant activation overrides other cell cycle arrest machinery, if those checkpoints are still in place. Importantly, its expression is increased exclusively in human LCC tissues ( Figure 3 and Table 3 ).
The results of the present study address a number of questions. First, they define genes whose expression is altered between adenomas and carcinomas in mouse lung. These gene products may be useful both as molecular targets as well as potential biomarkers of early tumor development. There is a possibility that some of the differentially expressed genes are due to differences in the density of mouse Type II cells or Clara cells in normal lungs versus lung tumors, with respect to the amounts of relative to stromal and other contaminating cells. We have not been successful in isolating pure Type II cells or Clara cells from the normal surrounding lungs of the animals bearing tumors. Furthermore, numerous steps and treatments required for the current methodology available for isolating these cells would not make the isolated cells suitable control cells for lung adenomas that did not undergo such a process for gene-expression-profiling studies. There is also a possibility that some of the gene-expression differences found during lung tumor progression (ADE versus CAR) are due to differences in the mouse backgrounds [(A/J Â 129/SvJ) F 1 mice versus (A/ J Â C3H/HeJ) F1 mice]. However, the majority of the gene-expression changes are tumor-specific changes because of the use of proper age-and strain-matched control lung tissues. Thus, most of these changes are valid and do reflect those involved in lung tumor progression. Second, we have shown that certain of the gene expression patterns found in mouse lung ACs recapitulate the gene expression differences found in embryonic tissue. This result may not be surprising since there are some functions in terms of cell division, lack of differentiation, and neovascularization, that must be similar for the two processes. Finally, we have compared the gene-expression patterns in murine lung cancers and human lung ACs and LCCs. It would appear that the human lung ACs are heterogenous, as previously reported, and that the mouse lung tumors seem to match the gene-expression patterns of human lung ACs and LCCs. The results of the present study begin to establish links between murine lung cancer and both murine lung development and human lung carcinogenesis.
